HIV Infections Clinical Trial
— URBANOfficial title:
Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
Verified date | October 2023 |
Source | ViiV Healthcare |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a prospective, non-interventional, multi-center study, in subjects with clinical indication of Human Immunodeficiency Virus (HIV)-1 infection. The aim of the study is to generate the real world evidence for the use of DTG+3TC in routine clinical care in Germany to supplement data obtained from controlled clinical trials. Approximately, 300 treatment naïve and pre-treated HIV-1 positive subjects will be enrolled in the study. The observation period for the study will be 3 years. Data will be collected from routine clinical care via electronic data capture (EDC) system.
Status | Active, not recruiting |
Enrollment | 300 |
Est. completion date | February 19, 2024 |
Est. primary completion date | July 28, 2023 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects with >= 18 years of age. - Subjects with documented HIV-1 infection. - Prescription of DTG + 3TC was issued independently from entering this study. - Subjects with the ability to understand informed consent form and other relevant regulatory documents. Exclusion Criteria: - Any contraindication according to Tivicay or Lamivudine summaries of product characteristics (SmPCs). - Subjects with VL > 500 c/mL. - Any antiretroviral therapy for the treatment of HIV-1 in addition to DTG and 3TC or the DTG/3TC fixed dose combination (FDC). - Subjects with hepatitis B virus (HBV)- coinfection. - Subjects with current participation in the ongoing non-interventional study TRIUMPH (study number: 202033, NCT number: NCT02342769) or in any interventional clinical trial irrespective of indication. - Subjects who had previously participated in clinical trials assessing DTG+ 3TC. |
Country | Name | City | State |
---|---|---|---|
Germany | GSK Investigational Site | Aachen | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Berlin | |
Germany | GSK Investigational Site | Bochum | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Hamburg | |
Germany | GSK Investigational Site | Hamburg | |
Germany | GSK Investigational Site | Koeln | |
Germany | GSK Investigational Site | Koeln | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Mannheim | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Muenchen | Bayern |
Germany | GSK Investigational Site | Muenchen | Bayern |
Germany | GSK Investigational Site | Muenchen | Bayern |
Germany | GSK Investigational Site | Osnabrueck | Niedersachsen |
Germany | GSK Investigational Site | Weimar |
Lead Sponsor | Collaborator |
---|---|
ViiV Healthcare | MUC Research GmbH |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of subjects with sustained virologic suppression, with Viral load (VL) < 50 Copies per Milliliter (c/mL) | Percentage of subjects with sustained virologic suppression, defined as VL <50 c/mL or if between 50-200 c/mL with a subsequent next available measurement <50 c/mL (within 120 days) will be evaluated. | Up to 36 months | |
Secondary | Percentage of pre-treated subjects with low level viremia | Percentage of subjects with low level viremia, defined as a VL measurement between >50 to <200 c/mL for pre-treated subjects will be evaluated. | Up to 36 months | |
Secondary | Percentage of naïve subjects with low level viremia after initial suppression | Percentage of subjects with low level viremia, defined as a VL measurement between >50 to <200 c/mL after initial suppression of <50 c/mL for naïve subjects will be evaluated. | Up to 36 months | |
Secondary | Percentage of virologic non-responders for naïve subjects | Percentage of virologic non-responders, defined as two consecutive measurements >=200 c/mL after at least 24 weeks of treatment in naïve subjects will be evaluated. | Up to 36 months | |
Secondary | Percentage of naïve subjects with virologic rebound | Percentage of naïve subjects with virologic rebound, defined as two consecutive VL measurements >=200 c/mL after suppression (one VL <50 c/mL) will be evaluated. | Up to 36 months | |
Secondary | Percentage of subjects with VL < 50 c/mL | Percentage of subjects with VL <50 c/mL will be evaluated. | Up to 36 months | |
Secondary | Percentage of subjects with two consecutive VL measurements of >=200 c/mL | Percentage of subjects with two consecutive VL measurements of >=200 c/mL will be evaluated. | Up to 36 months | |
Secondary | Percentage of subjects with treatment switch | Percentage of subjects with treatment switch due to virologic failure (VF) or due to intolerability determined at the discretion of the physician will be evaluated. | Up to 36 months | |
Secondary | Percentage of subjects with VL > 50 c/mL with emergent resistance mutations | Percentage of subjects with VL >50 c/mL with emergent resistance mutations will be summarized. Resistance analysis will be performed at the physician's discretion. | Up to 36 months | |
Secondary | Number of monitoring measures | Number of monitoring measures (normalized to subject years) will be summarized. | Up to 36 months | |
Secondary | Number and frequency of serious adverse events (SAE) | An SAE is any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant. | Up to 36 months | |
Secondary | Number and frequency of adverse drug reactions (ADRs) | An ADR is defined as a noxious and unintended response to a medicinal investigational product related to any dose where at least a reasonable possibility, that is the relationship cannot be ruled out. | Up to 36 months | |
Secondary | Adherence to therapy | Adherence to therapy will be determined from the number of monthly doses missed. | Up to 36 months | |
Secondary | Change from Baseline for lipid laboratory parameter: lactate dehydrogenase (LDH) | Lipid laboratory parameter LDH data will be evaluated at indicated time points. | Baseline and up to 36 months | |
Secondary | Change from Baseline for lipid laboratory parameters: cholesterol and triglycerides | Lipid laboratory parameters cholesterol and triglycerides data will be evaluated at indicated time points. | Baseline and up to 36 months | |
Secondary | Change in treatment satisfaction based on HIV Treatment Satisfaction questionnaire (HIV TSQ) | The HIV TSQ is a 10-item-self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience and flexibility. In treatment satisfaction score will range from 0-60, higher the score, greater the satisfaction with treatment. Individual item scores which included All rate score ranging from 0 (very dissatisfied, inconvenient, inflexible) to 6 (very satisfied, convenient, flexible), in case of general satisfaction , there will be 10 items which will be summed to produce a score ranging from 0 to 30, with higher the score greater the satisfaction with subscale. For lifestyle scale with 8 items which will be summed to produce a score ranging from 0 to 30, with higher the score greater the satisfaction with subscale. | Up to 36 months | |
Secondary | Change in Symptom Distress based on HIV Symptom Distress Module questionnaire | The Symptom Distress Module is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. This included sub-scales change in treatment satisfaction, individual satisfaction with treatment change. Treatment satisfaction score summed all items to produce scores ranging from +30 to -30, higher the score, greater the improvement in satisfaction with treatment, lower score greater is the deterioration in satisfaction. Individual item scores which included All rate score ranging from +3 (much more satisfied, much more convenient, much more flexible) to -3 (much less satisfied, much less convenient, much less flexible). General satisfaction and life style scores all items summed to produce score range +15 to -15, where higher the score greater the improvement in satisfaction, lower score greater is the deterioration in satisfaction. | Up to 36 months | |
Secondary | Reasons for switching to/prescription of DTG plus 3TC | The reasons for switching to/prescription of DTG plus 3TC as selected by the investigator from a pre-specified list will be summarized | Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT06072443 -
AURORA Study-A Transformative Approach to Support PrEP Medication Persistence
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|